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Abstract 
Background: Biocompatible gold nanoparticles (GNPs) are potentially practical and efficient agents in cancer 
radiotherapy applications. In this study, we demonstrated that GNPs can significantly modulate irradiation response 
of hepatocellular carcinoma cells in vitro and investigated the underlying mechanisms. We co‑grafted galactose 
(GAL) targeting hepatocyte specific asialoglycoprotein receptor and Polyethylene Glycol (PEG) onto GNPs surfaces to 
increase GNPs targeting specificity and stability.
Results: This novel GAL‑PEG‑GNPs and bare GNPs show similar appearance and cytotoxicity profiles, while more GAL‑
PEG‑GNPs can be effectively uptaken and could enhance cancer cell killing.
Conclusion: GAL‑PEG‑GNPs have better radiosensitization to HepG2. The sensitization mechanism of GAL‑PEG‑GNPs 
is related to the apoptotic gene process activated by generation of a large amount of free radicals induced by GNPs.
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Background
Radiation therapy plays an increasingly important role in 
the treatment of hepatocellular carcinoma (HCC), par-
ticularly in the management of locally advanced unre-
sectable HCC [1, 2]. However, radiation-induced liver 
disease and radiation resistance are major factors that 
limit the success of radiation therapy [3–5]. To improve 
the effectiveness of radiation therapy, image-guided radi-
ation that provides real-time imaging of the tumor target 
during treatment has been study. Real-time imaging can 
help compensate for normal movement of the internal 
organs from breathing and for changes in tumor size dur-
ing treatment. Moreover, in contrast to tumor control 
it enables full therapeutic efficacy while reducing the 
degree and frequency of invasive interventions [6].
On the other hand, radioprotectors and radiosensitiz-
ers, chemicals that modify a cell’s response to radiation 
are also under development. Radioprotectors are drugs 
that protect normal cells from damage caused by radia-
tion therapy [7]. In contrast, radiosensitizers make tumor 
cells more susceptible to radiation damage and can 
increase the damaging effects of radiation while mini-
mizing exposure to normal and healthy cells [8]. Several 
radiosensitizers, such as misonidazole, metronidazole, 
tirapazamine, trans sodium crocetinate are under study 
[9]. In addition, some anticancer drugs, such as 5-fluoro-
uracil and cisplatin, can make cancer cells more sensitive 
to radiation therapy as well [10–12]. Together, radiosen-
sitizers could enable radiation therapy at a lower dose, 
but would not affect treatment efficiency.
Nanoparticles have played a key role in the enhance-
ment of the radiation therapy by acting as both a thera-
peutic and a carrier for other therapeutics. Particularly, 
inert and biocompatible gold nanoparticles (GNPs) with 
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tunable size and low osmolality hold many potential 
advantages [13]. Gold absorbs approximately 3-times 
more than iodine at 20 and 100 keV; the dose enhance-
ment factor for gold is adjustable depending on the 
beam’s energy and the amount of gold delivered; the bio-
distribution of GNPs can be imaged in real time before 
a therapeutic dose is delivered and used for treatment 
planning and quantified prediction of dose enhance-
ment; moreover, GNPs allow surface immobilization of 
antibodies, peptides, aptamers or drugs. Thus, in recent 
years, using GNPs to enhance the radiation absorbed 
dose deposited in tumors from X-ray has gained increas-
ing attention [14–17]. Ligands functionalized GNPs 
could enhance radiation sensitivity in radiation-resist-
ant human prostate cancer cells at keV and MeV X-rays 
[15]. Chithrani et al. also showed a range of cell line spe-
cific responses including decreased clonogenic survival, 
increased apoptosis and induction of DNA damage could 
be induced when exposure to 1.9  nm GNPs and X-rays 
[17].
Ligands against cancer cell surface biomarkers or extra-
cellular matrix proteins have led to the applications of 
ligands for specific delivery of therapeutic agents [18]. 
Asialoglycoprotein receptor (ASGPR) is a hepatocyte-
specific receptor, and approximately 5 × 105 ASGPRs are 
expressed on the sinusoidal surface of a single liver cell 
[19]. ASGPR mediates the capture and endocytosis of 
galactose- or N-acetylgalactosamine-terminating glyco-
proteins [19, 20]. Thus, galactose, asialofetuin, acetylga-
lactosamine and asialoorosomucoid targeting ASGPR are 
commonly used as homing agents for drug delivery [21].
We propose that ASGPR-targeted GNPs may enhance 
the cytotoxic effects of radiation therapy, as well as 
concentrate the effect on targeted tumor cells in tissue. 
β-d-galactose (GAL) as a homing agent thus is immobi-
lized onto bare GNPs surfaces. Further, to prevent GNPs 
from being quickly phagocytosed by reticuloendothe-
lial system (RES) [22], biodegradable and biocompatible 
polyethylene glycol (PEG) is co-grafted to form a novel 
composite known as GAL-PEG-GNPs (Fig.  1). Results 
showed that compared to bare GNPs, GAL-PEG-GNPs 
can be more quickly and effectively uptaken by ASGPR 
over-expressed HepG2 cells. HepG2 cells treated by 
GAL-PEG-GNPS showed significant DNA double-strand 
breaks and cell apoptosis after 6-MeV X-rays irradiation. 
These results demonstrated that our GAL-PEG-GNPs 
hold potential as a radiosensitizer for HCC therapy.
Results
Characterization of GAL‑PEG‑GNPs
There was no significant difference in appearance 
between GNPs solution and GAL-PEG-GNPs solution 
(Fig. 2a). Highly monodisperse GNPs had approximately 
20 nm gold cores and average diameters of about 23 nm. 
In contrast, GAL-PEG-GNPs had dimensions between 
13 and 74 nm with a mean size of 34 nm (Fig. 2b). UV–
Vis spectroscopy showed that the GNPs and GAL-PEG-
GNPs exhibited strong absorption peak at 520 and 
523 nm, respectively (Fig. 2c). Further, GNPs and GAL-
PEG-GNPs were stained with 2 % phosphotungstic acid. 
In contrast to GNPs, GAL-PEG-GNPs displayed a thin 
white ring structure on surface (Fig. 2d), indicating well 
attachment of GAL on GNPs surface.
CCK8 assay
A colorimetric CCK8 assay was performed to meas-
ure the cytotoxicity of either GNPs or GAL-PEG-GNPs 
at various concentrations in cultured HepG2 cells. 
Fig. 1 The schematic diagram of preparation of GNPs and GAL‑PEG‑GNPS. GNPs in 20 nm diameter were prepared using sodium citrate reduction 
method. To prepare GAL‑PEG‑GNPs, 0.1 mL of bare GNPs at 0.1 mg/L (pH 7.5) were mixed with excessive amount of thiol‑PEG‑amino and incubated 
at 4 °C overnight, followed by thiol‑PEG grafting. 100 μL of sulfo‑NHS and EDC (5:1, pH 5.0) were incubated with 20 μg of GAL for 6 h at 37 °C to 
active carboxyl groups of GAL first, and 20 μL of PEGylated GNPs at 0.1 mg/L (pH 7.2) were incubated with the mixture at 37 °C for 2 h to finally 
produce GAL‑PEG‑GNPs
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The results showed that cell viability from both groups 
decreased with the increasing concentration of nano-
particles. However, there was a significant difference 
in cell inhibition rate between GNPs-treated cells and 
GAL-PEG-GNPs-treated cells (p < 0.05) (Fig. 3). Further, 
the IC50 value of GNPs and GAL-PEG-GNPs in HepG2 
cells was determined to be 5.001 and 4.997  μg/mL, 
respectively.
Uptaking GAL‑PEG‑GNPs by HepG2 Cells
The amount of gold uptake was measured by ICP-MS 
(Fig. 4). No gold was detected in the unexposed control 
group. In GNPs-treated cells, the gold uptake clearly 
increased with the incubation time, and the amount of 
gold reached a peak at 24 h time point. In the subsequent 
48–96  h, GNPs were gradually metabolized from cells 
and thus the amount of GNPs decreased accordingly. In 
contrast, the amount of GAL-PEG-GNPs uptaken by cells 
reached a peak at 8 h time point, and approximately three 
times more gold in cells compared to GNPs-treated cells 
(p  <  0.001). The results indicated that GAL-PEG-GNPs 
could be more quickly and effectively uptaken by HepG2 
cells in  vitro. TEM images further confirmed that the 
amount of GAL-PEG-GNPs uptaken in HepG2 cells was 
much higher than that of GNPs (Fig. 5). Both GNPs and 
GAL-PEG-GNPs mainly distributed in mitochondria.
Cell cycle
After exposure of cells to radiation cells showed 
varying proportion in S phase, 31.65  % in control 
group, 23.97  % in GNPs-treat group, and 17.67  % in 
Fig. 2 Characterization of nanoparticles. a Shows appearance of 
GNPs (left) and GAL‑PEG‑GNPs (right); b shows size distribution of 
GNPs (blue) and GAL‑PEG‑GNPs (red), respectively; c shows absorption 
peak of GNPs (blue) and GAL‑PEG‑GNPs (red), respectively; d shows 
the images of GNPs (left) and GAL‑PEG‑GNPs (right) detected by TEM
Fig. 3 Cytotoxicity of GNPs and GAL‑PEG‑GNPs at various concen‑
trations in HepG2 cells. The abscissa indicates drug concentration; 
the ordinate indicates cell inhibition rate. A colorimetric CCK8 assay 
was performed to measure the cytotoxicity; the measurements fol‑
low vender’s protocol
Fig. 4 Amount of GNPs and GAL‑PEG‑GNPs uptaken by HepG2 
cells at various timepoints. The Abscissa indicates time; the ordinate 
indicates numbers of GNPs in one cell. Cells were resuspend in 5 mL 
of 1× PBS and lysed using 5 mL of Aqua Regia (HNO3:HCL = 1:3) solu‑
tion at RT for 48 h. Concentration of Au in lysates was determined by 
ICP‑MS
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GAL-PEG-GNPs-treated one, respectively (Fig.  6). In 
contrast, cell proportion in G2/M phase increased from 
8.09 % in control group to 20.26 % in GNPs-treat group 
and further to 27.03 % in GAL-PEG-GNPs-treated group 
(p < 0.01).
Clonogenic assay
The clonogenic survival of HepG2 cells was assessed by 
treating the cells with X-ray alone or combining X-ray 
with either GNPs or GAL-PEG-GNPs. The results 
showed that cell viability from all three groups decreased 
with increasing radiation dose (Fig. 7). It was noted that 
cell viability in GAL-PEG-GNPs/X-ray treated group was 
significantly lower than that of the rest two groups from 
1 to 8  Gy (p  <  0.05), indicating GAL-PEG-GNPs could 
enhance radiation sensitivity of HepG2 cells to X-ray. 
According to the fitting cell survival curve, obtained 
by D0, the SERs of GNPs/X-ray group and GAL-PEG-
GNPs/X-ray group were 1.46, and 1.95, respectively.
Immunofluorescence γ‑H2AX Assay
The DNA-DSBs in HepG2 cells exposed to 0.5 Gy X-ray 
(6 MeV) was measured by the γ-H2AX assay. Untreated 
cells, GNPs- or GAL-PEG-GNPs-treated cells without 
radiation exposure did not show DNA-DSBs. In contrast, 
the formation of γ-H2AX foci in GNPs- and GAL-PEG-
GNPs-treated cells with radiation exposure appeared to 
be 4.5- and 8.6-fold respectively (p < 0.001) higher than 
that of cells with radiation exposure only (Fig. 8).
Western blot assay
The expressions of Cytochrome C, Bax, caspase-3, cas-
pase-9, and Bcl-2 in cells treated with radiation alone, 
GNPs/radiation, or GAL-PEG-GNPs/radiation were 
measured using Western blotting (Fig. 9). The expression 
of Cytochrome C, Bax, caspase-3, and caspase-9 were 
upregulated while Bcl-2 expression was downregulated 
in cells treated with GNPs/radiation or GAL-PEG-GNPs/
radiation. These results indicated that gold nanomaterials 
could induce more expression of intracellular apoptotic 
molecules and significantly inhibit expression of anti-
apoptotic protein in comparison with cells treated with 
radiation only.
Expression changes of CAT, SOD and GSH
The levels of three antioxidant proteins, CAT, SOD and 
GSH that have been used to quantify oxidative stress 
in cells were measured. Compared with cells treated 
with radiation, the activity of CAT, SOD, and GSH in 
the GNPs-treated HepG2 cells with radiation expo-
sure decreased 74.22, 84.13, and 76.47  %, respectively 
(p < 0.01). Meanwhile, the activity of CAT, SOD and GSH 
in GAL-PEG-GNPs-treated cells with radiation expo-
sure decreased 51.56, 61.16, and 54.90  %, respectively 
(p  <  0.01). There was a significant difference in expres-
sion of these proteins between two experimental groups 
(p < 0.01) as well (Table 1).
Discussion
Nanoparticles can permeate leaky angiogenic endothe-
lium providing some tumor specificity. Addition-
ally, blood clearance of nanoparticles is slower than 
small molecules, such as iodine contrast media, and 
thus nanoparticles can stay in the blood for hours [23]. 
Moreover, drugs can be bound to the nanoparticles or 
be entrapped inside the nanoparticles, allowing flexible 
Fig. 5 TEM images of GNPs (a) and GAL‑PEG‑GNPs (b) uptake in HepG2 cells. Images were taken by FEI Tecnai Spirit transmission electron micros‑
copy (JEM‑100CX II, Japan) at 200 kV
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and multifunctional therapy [24]. Nevertheless, nano-
particles have the potential to revolutionize cancer diag-
nosis and therapy [25]. Among various nanomaterials, 
particularly GNPs are very attractive. They can be safely 
administered with minimal inflammatory activation and 
few side effects. GNPs are very convenient to realize a 
variety of surface functionalization with various biologi-
cal molecules to help improve stability, drug-carrying, 
and tumor-targeting [12]. Furthermore, gold allows high 
absorption and enhancement of ionizing radiation, as 
well as superior X-ray attenuation for biomedical imag-
ing application. Moreover, other physical properties 
including surface plasmon resonance and Raman scat-
tering activity have been exploited in fluorescent imag-
ing, photothermal therapy, and many other applications 
[26, 27]. At KeV or MeV radiation energies, GNPs can 
selectively improve radiosensitivity of tumor cells lead-
ing to increased cell killing and have been trialed on vari-
ous cancer cell lines and animals [28–31]. Theoretically, 
the dose enhancement achieved by GNPs could be more 
than 200 % [16]. Though the mechanisms are still unclear, 
radiosensitization is generally attributed to increasing 
photo absorption of high-Z elements, and the resulting 
transfer of a larger portion of primary ionizing photon 
energy to tumor tissue.
Our previous results showed that bare GNPs could 
improve the radiosensitivity of HepG2 cells, elevate DNA 
damage levels, and induce cancer cells apoptosis in vitro 
[14]. To deliver a high dose of GNPs directly to malig-
nant cells, and to specifically radiosensitize them while 
minimizing side-effects, we further graft GAL targeting 
ASGPR for delivering GNPs to HepG2 cells in vitro. First 
of all, GNPs were prepared by sodium citrate reduction 
followed by surface functionalization with SH-PEG-NH2 
molecules and surface deactivation using SH-PEG mol-
ecules. The grafted amine groups were used to covalently 
immobilize GAL.
The size of GNPs for liver cancer therapy should not 
exceed 200  nm, since the size of liver sinusoidal fenes-
trations have 200  nm effective size limit. On the other 
hand, GNPs may experience rapid renal clearance if 
they are smaller than 10 nm in diameter. Size is also an 
influencing radiation sensitivity parameter, and large 
sized GNPs have superior dose enhancement factor [32, 
33]. Bergen et al. tested the efficacy of GNP size ranging 
Fig. 6 Cell cycle distribution of HepG2 was detected by flow 
cytometry (n = 3). a Control: G0/G1 phase (60.26 ± 2.96) %, S 
phase (31.65 ± 0.81) %, G2/M phase (8.09 ± 2.2) %. b GNPs: G0/
G1 phase (55.89 ± 1.7) %, S phase (23.97 ± 0.54) %, G2/M phase 
(20.26 ± 2.09) %, c GAL‑PEG‑GNPs: G0/G1phase (55.39 ± 1.25) %, S 
phase (17.67 ± 1.01) %, G2/M phase (27.03 ± 0.7) %. (p < 0.01) com‑
pared to Control; (p < 0.01) compared to Control and GNPs group
◂
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from 50 to 150 nm and concluded that GNPs in 50-nm 
diameter could have the highest radio enhancement fac-
tor (1.43 at 220  keV) and also have the highest cellular 
uptake [16]. However, a recent report showed that GNPs 
in 18-nm diameter have more cell internalization [34]. 
Though the optimal size of GNPs is inconclusive so far, 
there is a tradeoff between effective dose enhancement 
of large GNPs and the effective clearance of small ones. 
This remains a hurdle for their application in cancer 
imaging and therapy. The average size of our GNPs and 
GAL-PEG-GNPs is 23 and 34  nm, respectively. There-
fore, our nanoparticles prepared in this study are in 
principle suitable, in terms of size for radiosensitization 
applications, exploiting the enhanced permeability and 
retention effect and avoiding renal clearance. The larger 
size and peak shift of GAL-PEG-GNPs are attributed to 
surface PEGylation and GAL grafting. PEGylation can 
further reduce the reticuloendothelial system uptake 
and thus significantly increase circulation time. In addi-
tion, PEGylation decreases aggregation of GNPs owing 
to passivated surfaces and increase solubility in buffer 
and serum due to hydrophilic ethylene glycol repeats. It 
was reported that PEGylated nanoparticles show higher 
tumor accumulation versus background.
Both GNPs and GAL-PEG-GNPs at various concen-
trations showed cytotoxicity, and their IC50 values are 
5.001 and 4.997  μg/mL, respectively. Compared to the 
published data of GNPs cytotoxicity [35], our GNPs are 
Fig. 7 Clonogenic assays demonstrate the radiosensitization effects 
of GNPs and GAL‑PEG‑GNPs to HepG2 cells. The cells were exposed 
to 0 to 8 Gy of 6 MeV X‑ray. A dose‑dependent clonogenic survival 
of HepG2 cells. The regression curves were fit to the linear‑quadratic 
model. The SERs of GNPs/X‑ray group and GAL‑PEG‑GNPs X‑ray group 
were 1.46, and 1.95, respectively
Fig. 8 Immage of γH2AX focus in HepG2 cells. a Shows the γH2AX focus in HepG2 cells. b Sows DSB induction as determined by the γ‑H2AX assay 
was quantified as focus integrated density per unit nucleus area using Image J software. Data represent the mean results from three independent 
experiments. Compared with the control group, *p < 0.001, compared with GNPs, **p < 0.001
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relatively less cytotoxic. In this study, we merely used 1/5 
concentration (1.0 μg/mL) to minimize the cytotoxicity 
on HepG2 cells, and thus such low level of cytotoxicity 
can be neglected.
ICP-MS analysis revealed that the amount of GAL-
PEG-GNPs endocytosed by HepG2 cells was approxi-
mately three times more than that of GNPs dose, 
suggesting GAL significantly increased the gold uptake. 
Although both internalizing and noninternalizing 
epitopes on cell membrane can be targeted, if ligands 
bind to noninternalizing ones, drugs or nanoparticles 
may accumulate around the cells and enter into cells 
either by passive diffusion or normal transport mecha-
nisms. In contrast, when GAL bind to internalizing 
epitopes, like ASGPR, the binding triggers ASGPR-
mediated uptake and hence GAL-PEG-GNPs uptake 
is thus more effective. TEM images showed that GNPs 
were mainly distributed in mitochondrion. Few reports 
have demonstrated a role for reactive oxygen free radi-
cals (ROS) or the involvement of mitochondria as 
mechanism of GNPs radiosensitization [36, 37]. In this 
study, we confirmed that elevated levels of DNA damage 
which may be a direct result of impaired mitochondrial 
function manifested by increased oxidation and loss of 
membrane potential, resulting in HepG2 cells prolifera-
tion inhibition. It was further confirmed by clonogenic 
analysis. After exposure of cells to various radiation 
doses (1–8  Gy zone), clone quantities in GAL-PEG-
GNPs-treated group were significantly less than that in 
GNPs-treated and control groups mainly due to more 
amount of gold uptake.
The cell cycle analysis showed that cells were propelled 
to enter G2/M phase. GAL-PEG-GNPs induced approxi-
mately 27  % of cells in the G2/M phase; the percentage 
was more than that of GNPs induced. G2/M phase is the 
most radiosensitive phase of a cell cycle, and thus more 
accumulation in G2/M phase can enhance the radiation 
sensitivity. It was reported that GNPs can trigger activa-
tion of the CDK kinases, leading cancer cells to accumu-
late in the G2/M phase [37, 38]. Additionally, p53 protein 
may mediated G1 arrest and p53-independent G2/M 
phase arrest over 2–10 h after radiation [39]. Moreover, 
cell cycle kinetics can be changed by GNPs after radia-
tion. Previous reports demonstrated that GNP radiosen-
sitization can increase sub G1 population or accumulate 
cells in G2/M. Additionally, surface functionalization of 
GNP using a range of different biological moieties not 
only enables them maintain stability and bio-compati-
bility but also leads to accumulation of GNPs in tumors 
compared to healthy tissues [40]. Thus, it is likely to pro-
vide significant therapeutic advantage and may potential 
benefit personalized medicine.
γ-H2AX assay results showed a significantly higher 
incidence of DNA-DSBs in GAL-PEG-GNPs-treated 
group as compared to that in GNPs-treated or con-
trol group. Decreased clonogenic survival of HepG2 
cells and increased DNA-DSBs demonstrated that 
Fig. 9 Expression of apoptotic proteins and anti‑apoptotic protein in HepG2 cells radiated by 0.5 Gy X‑ray
Table 1 CAT/SOD/GSH changes in  HepG2 cells detected 
by the Microplate reader (mean ± SD)
Group CAT (U/g) SOD (U/mg) GSH (μmol/g)
Control 128 ± 4.35 466 ± 5.19 51 ± 2.08
GNPs 95 ± 7.09 392 ± 8.54 39 ± 2
GAL‑PEG‑GNPs 66 ± 6.56 285 ± 7.94 28 ± 1.15
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GAL-PEG-GNPs achieved better radiotherapy sensitiza-
tion effect compared to bare GNPs.
Significantly upregulated expression of Cytochrome 
C, Bax, Caspase-3, and Caspase-9 and downregulated 
anti-apoptotic protein Bcl-2 were found in GAL-PEG-
GNPs-treated cells after radiation. We found antioxidant 
enzymes including CAT, SOD, and GSH were significantly 
reduced indicating the increase of free radicals in HepG2 
cells. The release of ROS can cause mitochondrial mem-
brane depolarization and oxidization, and subsequently 
attack intercellular macromolecules, such as DNA, RNA, 
proteins, leading to above mentioned changes [31, 32]. 
The cytochrome C, which was released from mitochon-
dria to cytoplasm activated Caspase-9; Caspases-9 fur-
ther activated Caspase-3 and others [33, 34]. Caspase-3 
caused chromatin pyknosis, DNA fragmentation, and 
DNA fracture leading to cell apoptosis [35]. In contrast, 
the mechanisms of upregulated Bax and downregulated 
Bcl-2 through GNPs-mediated radiation are not clear yet, 
and thus should be further investigated in the future.
Conclusions
In this study, we successfully prepared GAL-PEG-GNPs 
as a novel radiosensitizer,found our novel nanoparticles 
could significantly improve the efficacy of radiotherapy 
in  vitro, and briefly discussed the mechanism of radio-
sensitization. Given the wide range of methods available 
to further modify these nanoparticles, in ongoing work 
we are also exploring the use of cell-specific internalizing 
aptamers (i.e. anti-EGFR aptamers or anti-EpCAM aptam-
ers) grafted PEG-GNPs that can more effectively be taken 
up by cancer cells overexpressing a cognate receptor, and 
the dual delivery of chemotherapeutic agents and GNPs to 
achieve a synergistic therapeutic outcome in  vivo. These 
vehicles may be able to circumvent biological barriers, 
such as the blood–brain barrier, thus resulting in efficient 
localization of various agents at the target sites.
Methods
Cell culture
The HepG2 cells were cultured in DMEM (GIBCO, 
Grand Island, USA) supplemented with 10 % heat-inacti-
vated fetal calf serum (FCS, GIBCO, Grand Island, USA) 
and 1 % penicillin–streptomycin (GIBCO, Grand Island, 
USA) at 37 °C under a humidified atmosphere containing 
5 % CO2 and maintained in an exponential growth state. 
Cells were passaged once every 3  days by using 0.25  % 
trypsin.
Preparation of GAL‑PEG‑GNPs
Synthesis of GNPs in 20  nm diameter was done with 
sodium citrate reduction method. The preparation 
method can be found elsewhere [21]. To graft amine 
groups onto bare GNPs surfaces, 0.1  mL of GNPs at 
0.1 mg/L (pH 7.5) were well mixed with excessive amount 
of thiol-PEG-amino (5000 Da, Seebio, ShangHai, China) 
and incubated at 4 °C overnight. The following thiol-PEG 
(5000 Da, Seebio, ShangHai, China) surface modification 
was performed to thoroughly replace the residual citrate 
groups. The products were purified and buffer exchanged 
into 1× PBS (pH 7.5) using ultrafiltration. 100  μL of 
N-hydroxysulfosuccinimide (sulfo-NHS) and carbodi-
imide (EDC) (5:1, pH 5.0) were incubated with 20 μg of 
GAL for 6 h at 37  °C to active carboxyl groups of GAL. 
At pH 7.2, 20 μL of PEGylated GNPs at 0.1  mg/L were 
added and incubated with the mixture at 37 °C for 2 h to 
finally produce GAL-PEG-GNPs (Fig.  1). The products 
were concentrated, filtered and stored at 4 °C.
Characterization of GAL‑PEG‑GNPs
Dynamic light scattering (DLS) was used to determine 
the size of GNPs. The DLS and Z-potential experiments 
were performed on a Malvern Zetasizer Nano ZS (Mal-
vern Instruments, Southborough, Massachusetts). Sam-
ples filtered followed by equilibration (typically 5  min) 
in a quartz cuvette to 37  °C. The software was arranged 
with the specific parameters of refractive index and 
absorption coefficient of the material and the viscosity of 
the solvent. DLS allows determination of hydrodynamic 
diameter of colloidal particles and conjugates, that is 
the diameter of sphere with the same Brownian motion 
as the analyzed particle. The concentration of GNPs and 
GAL-PEG-GNPs were determined by using inductively 
couple plasma mass spectrometry (ICP-MS). UV–vis-
ible adsorption spectrum of GNPs or GAL-PEG-GNPs 
was acquired over the wavelength range from 250 to 
800 nm with UV-2450 spectrophotometer (Tianjin Gang-
dong Sci. & Tech. Development CO. LTD, China) using 
quartz cuvettes with an optical path length of 0.5 cm at 
room temperature (RT). The size and morphology of 
GAL-PEG-GNPs are analyzed by FEI Tecnai Spirit trans-
mission electron microscopy (TEM) (JEM-100CX II, 
Japan) at 200 kV using AnalySIS software (Soft Imaging 
Systems).
CCK8 assay
The CCK8 assays were performed as instructed by the 
manufacturer to assess cell viability. Briefly, the cells were 
seeded in 96-well plates (approximately 3000 cells/well). 
GNPs and GAL-PEG-GNPs were diluted to various con-
centrations in 1× PBS (pH 7.4), then added into the wells. 
After 24 h incubation, 20 μL CCK8 (keygentec company, 
Nanjing, Jiangsu, China) was added to each well for 4 h. 
Optical density (OD) was measured at 490  nm using a 
Microplate reader (BioRad, DG3022, USA) and the pro-
liferation index was calculated as experimental OD value/
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control OD value. Estimate value of 50 % inhibition con-
centration (IC50).
ICP‑MS assay
The assay was performed in triplicate. A total of 1 × 106 
HepG2 cells were seeded onto a culture dish (dia. 15 mm) 
and cultured for 24 h. When the cells reached a 70 % con-
fluence, cells were exposed to GNPs (1/5 IC50 = 1.0 μg/
mL) and GAL-PEG-GNPs (1/5 IC50  =  1.0  μg/mL) at 
37 °C for 1, 2, 4, 8, 12, 24, 48, 72, 96 h, respectively. Cells 
were washed with 1× PBS twice, detached with 0.25  % 
trypsin, and suspend in 5 mL of 1× PBS. 5 mL of Aqua 
Regia (HNO3:HCL = 1:3) solution was added to cell sus-
pension to fully lyse cells at RT for 48 h. Concentration 
of Au in lysates was determined by ICP-MS, the total 
number of nanoparticles and cells were recorded as n and 
N, respectively. Thus, the number of nanoparticles con-
tained in each cell calculated as n/N.
Transmission electron microscopy
A total of 1 × 106 HepG2 cells were seed onto a culture 
dish (dia. 15  mm) and cultured for 24  h. After another 
24 h of incubation with GNPs or GAL-PEG-GNPs, cells 
were fixed by 4 % paraformaldehyde/2.5 % glutaraldehyde 
in PBS (0.7 mL) for 3 h. The cells were next rinsed with 
PBS and post-fixed using 1 % aqueous solution of OsO4 
(0.5 mL) for 1 h. Subsequently, the cells were washed with 
DI water, 30  % ethanol solution and stained with 0.5  % 
uranyl acetate (0.5  mL, in 30  % ethanol) for 1  h. Cells 
were then gradually dehydrated using a series of etha-
nol solutions (30, 60, 70, 80, and 100 %) and embedded 
in epoxy resin. The resin was polymerized at 60  °C for 
48  h. Ultra-thin sections (70–100  nm) were cut using a 
diamond knife on a Leica Ultramicrotome and mounted 
on Formvarcoated copper grids. The sections were then 
post-stained with 5 % uranyl acetate in 50 % ethanol and 
2 % aqueous lead citrate solution and imaged with TEM 
at 200 kV.
Cells cycle assay
The cells exposed to 0.25 Gy X-ray (6 MeV, Medical lin-
ear accelerator, Germany Siemens Primus Company) 
after incubating with GNPs (1.0  μg/mL) or GAL-PEG-
GNPs (1.0  μg/mL) for 24  h and then were harvested 
using 0.25 % trypsin with 1 mM EDTA solution and fixed 
for 12 h in 70 % ethanol at 4 °C. The fixed cells were then 
centrifuged at 3000 rpm for 15 min to remove the ethanol 
thoroughly. The cells were then washed twice with 3 mL 
of PBS, resuspended in 1 mL of PI (Sigema, USA) stain-
ing solution, and incubated for 15 min at RT. The staining 
solution consisted of 20 mg/mL PI and 0.2 mg/mL RNase 
in PBS. The samples were subsequently analyzed using 
a BD FACS CantoII instrument (BD Biosciences, USA). 
Twenty thousand events were collected from each sam-
ple. The percentages of cells in the G0/G1, S, and G2/M 
phases of the cell cycle were determined using the Mod-
Fit software (BD, USA).
Clonogenic assay
The radiosensitization of GAL-PEG-GNPs or GNPs to 
HepG2 cells were assessed by the clonogenic assay. Dif-
ferent number of HepG2 cells (100, 300, 1000, 5000, 
10,000) were plated in 6-well and incubated with GNPs 
(1.0  μg/mL) or GAL-PEG-GNP (1.0  μg/mL) for 24  h, 
then irradiated with 0, 1, 2, 4, 6, 8 Gy X-ray and incubated 
for 9–14 days. The colonies were fixed with methanol and 
stained with 0.4 % crystal violet. Finally, the plates were 
inspected by microscopy and the number of the colo-
nies was counted. Each assay was made in triplicate and 
only colonies containing at least 50 cells were counted. 
The sensitizer enhancement ratio (SER) was calculated as 
the radiation dose needed for radiation alone divided by 
the dose needed for various concentrations of nanopar-
ticles plus radiation at a survival fraction of 37 % (D0 in 
radiobiology).
DNA damage immunofluorescence microscopy
The ability of GAL-PEG-GNPs or GNPs to enhance DNA 
double-strand breaks (DSBs) in HepG2 cells exposed 
to 0.5  Gy X-ray was evaluated using the γ-H2AX assay. 
This assay detects the phosphorylation of histone-H2AX 
at serine-139 (γ-H2AX), which is visualized as discrete 
nuclear foci by laser confocal microscopy using γ-H2AX-
specific antibodies.
Cells were cultured (6  ×  104 cells/well) on 24-well 
plates overnight at 37 °C in medium. After 24 h, the cul-
ture medium was replaced with 300 mL of fresh medium 
or medium containing GAL-PEG-GNPs or GNPs, 
respectively, and incubated overnight at 37  °C. The 
treated cells were then exposed to 0.5 Gy of X-radiation 
using an X-ray source, operating at 6  MeV. Cells were 
subsequently fixed using 4 % paraformaldehyde (Sigma-
Aldrich, USA), permeabilized with 0.5  % Nonidet P40 
(Sigma-Aldrich, USA) in PBS for 15 min, and blocked in 
2  % bovine serum albumin (BSA, Sigma-Aldrich, USA) 
for 1  h at RT. Cells were then incubated with anti-γ-
H2AX mouse monoclonal IgG1 (Upstate Biotechnology, 
Billerica, MA, USA) at a 1:800 dilution in 3  % BSA-
PBS overnight at 48  °C and then with anti-mouse IgG 
(H  +  L) (Invitrogen Molecular Probes, Carlsbad, CA, 
USA) at 1:500 dilution for 45  min at RT. Cover glasses 
were mounted on microscope slides (25 × 75 × 1 mm, 
Fisherbrand, Fisher Scientific Co.) The edges of cover 
glasses were sealed with clear nail polish. From the step 
using the secondary antibody onwards, all procedures 
were performed in the dark. Cover glasses were wrapped 
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in aluminum foil and stored at 4 °C for later image acqui-
sition. Images of γ-H2AX foci and nuclei were acquired 
with a Confocal Microscope Images were taken with 
an inverted laser confocal microscope (Zeiss510, Ger-
many). Excitation was at 364 or 488  nm for visualiza-
tion of DAPI or AlexaFluor-488 with emission filters of 
385–470  nm or 505–550  nm, respectively. The number 
of γ-H2AX foci present in each cell was quantified with 
Image J software (version 1.36b, National Institutes of 
Health) using customized macros recently developed by 
our group.
Western blot analysis
Cellular proteins were extracted, quantified, and sub-
jected to sodium dodecylsulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE, keygentec company, KGP113). 
Proteins samples were then blotted onto a nitrocellu-
lose membrane. After incubation with a blocking buffer, 
the membranes were incubated for 2 h at RT with each 
primary antibody at the appropriate dilution, as recom-
mended by the supplier. Antibodies included Bax, Bcl-2, 
Caspase-3, Caspase-9, and Cytochrome C. After wash-
ing, the membranes were subsequently incubated for 
1 h at RT in Goat Anti-mouse Immunoglobulin G (IgG, 
keygentec company, KGAA36) followed by the use of 
enhanced chemiluminescence kits. β-actin was used as 
an internal control.
Expression of CAT, SOD, and T‑GSH in HepG2 cells14
Catalase (CAT) activity was estimated by the method 
of Aebi. Activity of the enzyme superoxide dismutase 
(SOD) was measured by nitro blue tetrazolium reduc-
tion method of McCord and Fridovich. The level of glu-
tathione (GSH) was assayed by the method of Moron 
et al. based on the reaction with dithiobis(2-nitrobenzoic 
acid). The method measured the rate of decomposition of 
hydrogen peroxide (H2O2) at 240 nm.
Statistical analysis
In the statistical analysis, differences between the treated 
and control groups were compared using Student’s t 
tests, with the differences at the P < 0.05 level considered 
to be statistically significant.
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